A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck

作者：Chun Stephen G; Hughes Randall; Sumer Baran D; Myers Larry L; Truelson John M; Khan Saad A; Ma Tsung Wei; Xie Yang; Yordy John S; Cooley Susan; Wu Jean; Choy Hak; Nedzi Lucien A^*

来源：Cancer Investigation, 2017, 35(1): 23-31.

DOI：10.1080/07357907.2016.1213275

• Abraxane
• head and neck cancer
• erbitux
• cisplatin
• radiation therapy

Nab-paclitaxel might impact efficacy of radiation for head and neck (H&N) cancer. Nab-paclitaxel, cisplatin, cetuximab, and radiation were evaluated in patients with locally advanced head and neck cancer in this phase I/II trial. Median follow-up was 24 months for 34 patients. The maximum tolerated dose of nab-paclitaxel was 20 mg/m(2) with 20 mg/m(2) cisplatin and 250 mg/m(2) cetuximab. The 2-year progression-free survival (PFS) was 60% (95% confidence interval (CI) 0.42, 0.78), local control 71%(95% CI 0.55, 0.87), and overall survival 68% (95% CI 0.50, 0.86). This is the first study evaluating these agents with radiation in humans, with similar 2-year PFS as historic control.

• 出版日期2017